Immune responses during spontaneous control of HIV and AIDS: what is the hope for a cure?

HIV research has made rapid progress and led to remarkable achievements in recent decades, the most important of which are combination antiretroviral therapies (cART). However, in the absence of a vaccine, the pandemic continues, and additional strategies are needed. The ‘towards an HIV cure’ initiative aims to eradicate HIV or at least bring about a lasting remission of infection during which the host can control viral replication in the absence of cART. Cases of spontaneous and treatment-induced control of infection offer substantial hope. Here, we describe the scientific knowledge that is lacking, and the priorities that have been established for research into a cure. We discuss in detail the immunological lessons that can be learned by studying natural human and animal models of protection and spontaneous control of viraemia or of disease progression. In particular, we describe the insights we have gained into the immune mechanisms of virus control, the impact of early virus–host interactions and why chronic inflammation, a hallmark of HIV infection, is an obstacle to a cure. Finally, we enumerate current interventions aimed towards improving the host immune response.

[1]  M. Lederman,et al.  Towards an HIV cure: a global scientific strategy , 2012, Nature Reviews Immunology.

[2]  M. Lederman,et al.  Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Xiping Wei,et al.  Antiviral pressure exerted by HIV-l-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus , 1997, Nature Medicine.

[4]  L. Weinberger,et al.  Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques , 1999, The Journal of experimental medicine.

[5]  C. Hallahan,et al.  Maintenance of Large Numbers of Virus-Specific CD8+ T Cells in HIV-Infected Progressors and Long-Term Nonprogressors , 2000, The Journal of Immunology.

[6]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[7]  L. Morris,et al.  The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.

[8]  L. Picker,et al.  IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. , 2009, Current HIV research.

[9]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[10]  R. Johnson,et al.  Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. , 2008, Cellular immunology.

[11]  M. Müller-Trutwin,et al.  Role for plasmacytoid dendritic cells in anti‐HIV innate immunity , 2005, Immunology and cell biology.

[12]  O. Lambotte,et al.  HIV Controller CD4+ T Cells Respond to Minimal Amounts of Gag Antigen Due to High TCR Avidity , 2010, PLoS pathogens.

[13]  V. Appay The physiological role of cytotoxic CD4+ T‐cells: the holy grail? , 2004, Clinical and experimental immunology.

[14]  M. Lederman,et al.  Interleukin-7 promotes HIV persistence during antiretroviral therapy. , 2013, Blood.

[15]  C. Rouzioux,et al.  Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy , 2001, AIDS.

[16]  Jerome H. Kim,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. , 2009, The New England journal of medicine.

[17]  Feng Gao,et al.  Phenotypic properties of transmitted founder HIV-1 , 2013, Proceedings of the National Academy of Sciences.

[18]  Steven M. Wolinsky,et al.  Relative resistance to HIV–1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high–risk sexual exposures , 1996, Nature Medicine.

[19]  D. Richman,et al.  Absence of detectable HIV-1 viremia after treatment cessation in an infant. , 2013, The New England journal of medicine.

[20]  H. Hatano Immune activation and HIV persistence: considerations for novel therapeutic interventions , 2013, Current opinion in HIV and AIDS.

[21]  Brigitte Autran,et al.  Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study , 2013, PLoS pathogens.

[22]  Steven G. Deeks,et al.  HLA Class I-Restricted T-Cell Responses May Contribute to the Control of Human Immunodeficiency Virus Infection, but Such Responses Are Not Always Necessary for Long-Term Virus Control , 2008, Journal of Virology.

[23]  Baek Kim,et al.  p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway , 2013, Proceedings of the National Academy of Sciences.

[24]  M. Dierich,et al.  Complement-HIV interactions during all steps of viral pathogenesis. , 2008, Vaccine.

[25]  C. Rouzioux,et al.  Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial , 2011, AIDS.

[26]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[27]  H. Schuitemaker,et al.  Low Immune Activation despite High Levels of Pathogenic Human Immunodeficiency Virus Type 1 Results in Long-Term Asymptomatic Disease , 2007, Journal of Virology.

[28]  Hendrik Streeck,et al.  Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. , 2005, Blood.

[29]  R. Lempicki,et al.  Evidence for innate immune system activation in HIV type 1-infected elite controllers. , 2014, The Journal of infectious diseases.

[30]  D. Montefiori,et al.  Functional Cure of SIVagm Infection in Rhesus Macaques Results in Complete Recovery of CD4+ T Cells and Is Reverted by CD8+ Cell Depletion , 2011, PLoS pathogens.

[31]  H. Agut,et al.  HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. , 2001, AIDS research and human retroviruses.

[32]  Jeffrey N. Martin,et al.  Prospective Antiretroviral Treatment of Asymptomatic, HIV-1 Infected Controllers , 2013, PLoS pathogens.

[33]  P. Tebas,et al.  Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir. , 1999, AIDS.

[34]  Charles R. Brown,et al.  Plateau Levels of Viremia Correlate with the Degree of CD4+-T-Cell Loss in Simian Immunodeficiency Virus SIVagm-Infected Pigtailed Macaques: Variable Pathogenicity of Natural SIVagm Isolates , 2005, Journal of Virology.

[35]  M. Gardner,et al.  Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. , 1986, Journal of interferon research.

[36]  R. Kaul,et al.  HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. , 1999, AIDS.

[37]  H. Ding,et al.  Relative resistance of HIV-1 founder viruses to control by interferon-alpha , 2013, Retrovirology.

[38]  A. Bergamaschi,et al.  Human TRIM Gene Expression in Response to Interferons , 2009, PloS one.

[39]  Jack T Stapleton,et al.  The Major Genetic Determinants of HIV-1 Control Affect HLA Class I Peptide Presentation , 2010, Science.

[40]  Todd M. Allen,et al.  TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection , 2012, Nature Immunology.

[41]  Rachel E. Owen,et al.  HIV+ elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses , 2010, AIDS.

[42]  M. Malim,et al.  Human MX2 is an interferon-induced post-entry inhibitor of HIV-1 infection , 2013, Nature.

[43]  F. Pereyra,et al.  Leukocyte Immunoglobulin-Like Receptors Maintain Unique Antigen-Presenting Properties of Circulating Myeloid Dendritic Cells in HIV-1-Infected Elite Controllers , 2010, Journal of Virology.

[44]  R. Steinman,et al.  Dendritic cell‐targeted protein vaccines: a novel approach to induce T‐cell immunity , 2012, Journal of internal medicine.

[45]  F. Pereyra,et al.  Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers , 2012, AIDS.

[46]  M. Carrington,et al.  Impact of protective killer inhibitory receptor/human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers , 2012, AIDS.

[47]  C. Rouzioux,et al.  CD4 Dynamics over a 15 Year-Period among HIV Controllers Enrolled in the ANRS French Observatory , 2011, PloS one.

[48]  H. Clifford Lane,et al.  Administration of an Anti-CD8 Monoclonal Antibody Interferes with the Clearance of Chimeric Simian/Human Immunodeficiency Virus during Primary Infections of Rhesus Macaques , 1998, Journal of Virology.

[49]  B. Clotet,et al.  A Dendritic Cell–Based Vaccine Elicits T Cell Responses Associated with Control of HIV-1 Replication , 2013, Science Translational Medicine.

[50]  Asier Sáez-Cirión,et al.  HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype , 2007, Proceedings of the National Academy of Sciences.

[51]  R. Ribeiro,et al.  Kinetics of Myeloid Dendritic Cell Trafficking and Activation: Impact on Progressive, Nonprogressive and Controlled SIV Infections , 2013, PLoS pathogens.

[52]  M. Carrington,et al.  Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. , 2013, The Journal of infectious diseases.

[53]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[54]  F. Pereyra,et al.  Elite Controllers with Low to Absent Effector CD8+ T Cell Responses Maintain Highly Functional, Broadly Directed Central Memory Responses , 2012, Journal of Virology.

[55]  D. Scott‐Algara,et al.  Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. , 2007, Blood.

[56]  H. Stein,et al.  Mucosal but not peripheral FOXP3+ regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. , 2006, Blood.

[57]  Jeffrey N. Martin,et al.  Evidence for Persistent Low-Level Viremia in Individuals Who Control Human Immunodeficiency Virus in the Absence of Antiretroviral Therapy , 2008, Journal of Virology.

[58]  Hui Li,et al.  Nef-Mediated Suppression of T Cell Activation Was Lost in a Lentiviral Lineage that Gave Rise to HIV-1 , 2006, Cell.

[59]  Lynn Morris,et al.  Evolution of an HIV glycan–dependent broadly neutralizing antibody epitope through immune escape , 2012, Nature Medicine.

[60]  P. Easterbrook,et al.  Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[61]  Jerome H. Kim,et al.  Impact of Multi-Targeted Antiretroviral Treatment on Gut T Cell Depletion and HIV Reservoir Seeding during Acute HIV Infection , 2012, PloS one.

[62]  E. Rosenberg,et al.  Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. , 2007, The Journal of infectious diseases.

[63]  M. Brameier,et al.  In Vivo Administration of a JAK3 Inhibitor during Acute SIV Infection Leads to Significant Increases in Viral Load during Chronic Infection , 2014, PLoS pathogens.

[64]  P. Sansonetti,et al.  Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. , 1995, AIDS research and human retroviruses.

[65]  J. Levy,et al.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. , 1986, Science.

[66]  S. Oka,et al.  Strong Ability of Nef-Specific CD4+ Cytotoxic T Cells To Suppress Human Immunodeficiency Virus Type 1 (HIV-1) Replication in HIV-1-Infected CD4+ T Cells and Macrophages , 2009, Journal of Virology.

[67]  J. Fellay,et al.  Role of retroviral restriction factors in the interferon-α–mediated suppression of HIV-1 in vivo , 2012, Proceedings of the National Academy of Sciences.

[68]  C. Bailey-Kellogg,et al.  Divergent Antibody Subclass and Specificity Profiles but Not Protective HLA-B Alleles Are Associated with Variable Antibody Effector Function among HIV-1 Controllers , 2013, Journal of Virology.

[69]  J. van Grevenynghe,et al.  Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. , 2012, Blood.

[70]  P. Morlat,et al.  Early evolution of plasma soluble TNF-alpha p75 receptor as a marker of progression in treated HIV-infected patients. , 2008, AIDS research and human retroviruses.

[71]  M. Altfeld,et al.  Evasion from NK cell-mediated immune responses by HIV-1. , 2012, Microbes and infection.

[72]  Terri Wrin,et al.  Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. , 2008, The Journal of infectious diseases.

[73]  Victor Appay,et al.  A molecular basis for the control of preimmune escape variants by HIV-specific CD8+ T cells. , 2013, Immunity.

[74]  Michael Y. Gerner,et al.  CD4 T follicular helper cell dynamics during SIV infection. , 2012, The Journal of clinical investigation.

[75]  Fan Wu,et al.  TRIM5 alpha Drives SIVsmm Evolution in Rhesus Macaques , 2013, PLoS pathogens.

[76]  F. Barré-Sinoussi,et al.  Acute Plasma Biomarkers of T Cell Activation Set-Point Levels and of Disease Progression in HIV-1 Infection , 2012, PloS one.

[77]  Jeffrey N. Martin,et al.  Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. , 2008, The Journal of infectious diseases.

[78]  D. Douek,et al.  Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts , 2009, Nature Medicine.

[79]  E. Rosenberg,et al.  Dendritic cell dysfunction during primary HIV-1 infection. , 2011, The Journal of infectious diseases.

[80]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[81]  L. Mayer,et al.  Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. , 1995, Clinical therapeutics.

[82]  J. Piccirillo,et al.  HLA alleles determine differences in human natural killer cell responsiveness and potency , 2008, Proceedings of the National Academy of Sciences.

[83]  E. Rosenberg,et al.  HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome , 2012, Science Translational Medicine.

[84]  M. Paiardini,et al.  HIV‐associated chronic immune activation , 2013, Immunological reviews.

[85]  B. Autran,et al.  Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. , 2013, Blood.

[86]  J. Tschopp,et al.  Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways , 1994, Nature.

[87]  B. Walker,et al.  Matrix Metalloprotease Inhibitors Restore Impaired NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Human Immunodeficiency Virus Type 1 Infection , 2009, Journal of Virology.

[88]  E. Zúñiga,et al.  Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. , 2008, Cell host & microbe.

[89]  M. Rosińska,et al.  Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. , 2012, Archives of internal medicine.

[90]  Qingsheng Li,et al.  Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells , 2005, Nature.

[91]  Robert F. Siliciano,et al.  Role of Natural Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro , 2009, Journal of Virology.

[92]  Martin Meier-Schellersheim,et al.  CD4 T Cell Depletion Is Linked Directly to Immune Activation in the Pathogenesis of HIV-1 and HIV-2 but Only Indirectly to the Viral Load1 , 2002, The Journal of Immunology.

[93]  D. Kaufmann,et al.  Role of PD-1 in HIV Pathogenesis and as Target for Therapy , 2012, Current HIV/AIDS Reports.

[94]  E. Riley,et al.  Differential Induction of TGF-β Regulates Proinflammatory Cytokine Production and Determines the Outcome of Lethal and Nonlethal Plasmodium yoelii Infections 1 , 2003, The Journal of Immunology.

[95]  M. Altfeld,et al.  Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine , 2011, AIDS.

[96]  C. Rouzioux,et al.  Spontaneous control of viral replication during primary HIV infection: when is "HIV controller" status established? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[97]  Jerome H. Kim,et al.  Protective Efficacy of a Global HIV-1 Mosaic Vaccine against Heterologous SHIV Challenges in Rhesus Monkeys , 2013, Cell.

[98]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[99]  H. Schuitemaker,et al.  The effecT of TrIm 5 PolymorPhIsms on The clInIcal course of hIV-1 InfecTIon , 2011 .

[100]  M. Kruhlak,et al.  Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[101]  A. Bergamaschi,et al.  Restriction of HIV-1 replication in macrophages and CD4+ T cells from HIV controllers. , 2011, Blood.

[102]  Jeffrey N. Martin,et al.  HIV Controllers with HLA-DRB1*13 and HLA-DQB1*06 Alleles Have Strong, Polyfunctional Mucosal CD4+ T-Cell Responses , 2010, Journal of Virology.

[103]  J. Lifson,et al.  Differential infection patterns of CD4+ T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. , 2012, Blood.

[104]  E. Wherry,et al.  Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. , 2012, Current opinion in HIV and AIDS.

[105]  Jeffrey N. Martin,et al.  A Low T Regulatory Cell Response May Contribute to Both Viral Control and Generalized Immune Activation in HIV Controllers , 2011, PloS one.

[106]  Matthew S. Lewis,et al.  Cytomegalovirus Vectors Violate CD8+ T Cell Epitope Recognition Paradigms , 2013, Science.

[107]  G. Pantaleo,et al.  Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production , 2013, The Journal of experimental medicine.

[108]  M. Dietrich,et al.  Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. , 1990, Lymphology.

[109]  Pamela Warner,et al.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand , 2010, Journal of Family Planning and Reproductive Health Care.

[110]  A. Fauci,et al.  Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. , 1989, Science.

[111]  J. Schmitz,et al.  A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. , 1999, The American journal of pathology.

[112]  S. Boni,et al.  Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation , 2013, Proceedings of the National Academy of Sciences.

[113]  F. Barré-Sinoussi,et al.  Plasmacytoid Dendritic Cell Dynamics and Alpha Interferon Production during Simian Immunodeficiency Virus Infection with a Nonpathogenic Outcome , 2008, Journal of Virology.

[114]  Jeffrey N. Martin,et al.  Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis , 2009, AIDS.

[115]  P. Roques,et al.  Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion , 2010, Retrovirology.

[116]  A. Blancher,et al.  Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque , 2011, Immunogenetics.

[117]  E. Rosenberg,et al.  Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[118]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[119]  Charles M. Rice,et al.  MX2 is an interferon-induced inhibitor of HIV-1 infection , 2013, Nature.

[120]  David Heckerman,et al.  CD8+ T-cell responses to different HIV proteins have discordant associations with viral load , 2007, Nature Medicine.

[121]  V. Simon,et al.  APOBEC3G Polymorphism as a Selective Barrier to Cross-Species Transmission and Emergence of Pathogenic SIV and AIDS in a Primate Host , 2013, PLoS pathogens.

[122]  F. Barré-Sinoussi,et al.  Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks , 2006, Retrovirology.

[123]  Thierry Prazuck,et al.  Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection , 2010, AIDS.

[124]  Myron S. Cohen,et al.  Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. , 2011, The Journal of infectious diseases.

[125]  O. Lambotte,et al.  HIV Controllers Maintain a Population of Highly Efficient Th1 Effector Cells in Contrast to Patients Treated in the Long Term , 2012, Journal of Virology.

[126]  C. Hallahan,et al.  Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. , 2008, Immunity.

[127]  J. Mellors,et al.  Nonhuman Primate Models for HIV Cure Research , 2012, PLoS pathogens.

[128]  Amalio Telenti,et al.  Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1 , 2007, Nature Genetics.

[129]  F. Pereyra,et al.  Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. , 2012, The Journal of infectious diseases.

[130]  Mario Roederer,et al.  Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection , 2005, Nature.

[131]  H. Liao,et al.  Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers , 2009, AIDS.

[132]  V. Maino,et al.  Insufficient Production and Tissue Delivery of CD4+Memory T Cells in Rapidly Progressive Simian Immunodeficiency Virus Infection , 2004, The Journal of experimental medicine.

[133]  Hui Li,et al.  Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection , 2008, Proceedings of the National Academy of Sciences.

[134]  B. Vuylsteke,et al.  Cutting Edge: Resistance to HIV-1 Infection among African Female Sex Workers Is Associated with Inhibitory KIR in the Absence of Their HLA Ligands1 , 2006, The Journal of Immunology.

[135]  R. Zinkernagel,et al.  CD8+ T cell‐mediated protection against an intracellular bacterium by perforin‐dependent cytotoxicity , 1994, European journal of immunology.

[136]  R. Siliciano,et al.  Challenges in Detecting HIV Persistence during Potentially Curative Interventions: A Study of the Berlin Patient , 2013, PLoS pathogens.

[137]  S. Heath,et al.  Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. , 2005, The Journal of infectious diseases.

[138]  Jaranit Kaewkungwal,et al.  The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 Envelope , 2012, The Journal of Immunology.

[139]  D. Kitch,et al.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[140]  A. Sáez-Cirión,et al.  HIV controllers: a genetically determined or inducible phenotype? , 2013, Immunological reviews.

[141]  Jeff E. Mold,et al.  Tryptophan Catabolism by Indoleamine 2,3-Dioxygenase 1 Alters the Balance of TH17 to Regulatory T Cells in HIV Disease , 2010, Science Translational Medicine.

[142]  A. Trkola,et al.  Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies , 2005, Nature Medicine.

[143]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[144]  Zhiwei Chen,et al.  PD1-based DNA vaccine amplifies HIV-1 GAG-specific CD8+ T cells in mice. , 2013, The Journal of clinical investigation.

[145]  B. Clotet,et al.  Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection , 2014, AIDS.

[146]  Jeffrey N. Martin,et al.  Epistatic interactions between Fc (GM) and FcγR genes and the host control of human immunodeficiency virus replication. , 2012, Human immunology.

[147]  E. Ruiz-Mateos,et al.  Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers , 2012, Journal of Virology.

[148]  F. Miedema,et al.  Persistent immune activation in HIV-1 infection is associated with progression to AIDS , 2003, AIDS.

[149]  R. Siliciano,et al.  Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. , 2012, Immunity.

[150]  I. Sereti,et al.  Can early therapy reduce inflammation? , 2014, Current opinion in HIV and AIDS.

[151]  R. Johnson,et al.  SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. , 2012, The Journal of infectious diseases.

[152]  Zhiwei Chen,et al.  PD 1-based DNA vaccine amplifies HIV-1 GAG-specific CD 8 + T cells in mice , 2013 .

[153]  A. Della Corte,et al.  A Highly Intensified ART Regimen Induces Long-Term Viral Suppression and Restriction of the Viral Reservoir in a Simian AIDS Model , 2012, PLoS pathogens.

[154]  R. Schooley,et al.  Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. , 2010, The Journal of infectious diseases.

[155]  K. Reimann,et al.  Blocking of α4β7 Gut-Homing Integrin during Acute Infection Leads to Decreased Plasma and Gastrointestinal Tissue Viral Loads in Simian Immunodeficiency Virus-Infected Rhesus Macaques , 2011, The Journal of Immunology.

[156]  C. Passaes,et al.  HIV cure research: advances and prospects. , 2014, Virology.

[157]  G. Dickson,et al.  Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1 , 2009, Proceedings of the National Academy of Sciences.

[158]  E. Ruiz-Mateos,et al.  Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferon-α and differentiate into functional killer pDCs under HIV activation. , 2012, The Journal of infectious diseases.

[159]  Eric Delwart,et al.  Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection , 2002, AIDS.

[160]  C. Rouzioux,et al.  Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[161]  Keith Hoots,et al.  Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS , 2002, Nature Genetics.

[162]  Tao Dong,et al.  Immune Activation and CD8+ T-Cell Differentiation towards Senescence in HIV-1 Infection , 2004, PLoS biology.

[163]  D. Douek,et al.  Reduction of Immune Activation with Chloroquine Therapy during Chronic HIV Infection , 2010, Journal of Virology.

[164]  F. Marincola,et al.  HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[165]  R. Phillips,et al.  HIV-1-specific CD4+ responses in primary HIV-1 infection predict disease progression , 2014, AIDS.

[166]  F. Barré-Sinoussi,et al.  Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. , 2005, The Journal of clinical investigation.

[167]  M. Betts,et al.  Flow cytometric detection of perforin upregulation in human CD8 T cells , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[168]  C. Larsen,et al.  Statin Therapy and Mortality in HIV-Infected Individuals; A Danish Nationwide Population-Based Cohort Study , 2013, PloS one.

[169]  A. Bergamaschi,et al.  The CDK Inhibitor p21Cip1/WAF1 Is Induced by FcγR Activation and Restricts the Replication of Human Immunodeficiency Virus Type 1 and Related Primate Lentiviruses in Human Macrophages , 2009, Journal of Virology.

[170]  Lewis H Kuller,et al.  Inflammatory and Coagulation Biomarkers and Mortality in Patients with HIV Infection , 2008, PLoS medicine.

[171]  G. Carcelain,et al.  Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[172]  Galit Alter,et al.  HLA Class I Subtype-Dependent Expansion of KIR3DS1+ and KIR3DL1+ NK Cells during Acute Human Immunodeficiency Virus Type 1 Infection , 2009, Journal of Virology.

[173]  R. König,et al.  SAMHD1-Deficient CD14+ Cells from Individuals with Aicardi-Goutières Syndrome Are Highly Susceptible to HIV-1 Infection , 2011, PLoS pathogens.

[174]  J. Routy,et al.  Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals , 2008, AIDS.

[175]  R. D’Aquila,et al.  Lower HIV Provirus Levels Are Associated with More APOBEC3G Protein in Blood Resting Memory CD4+ T Lymphocytes of Controllers In Vivo , 2013, PloS one.

[176]  D. Douek Immune activation, HIV persistence, and the cure. , 2013, Topics in antiviral medicine.

[177]  D. Ho,et al.  Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome , 1994, Journal of virology.

[178]  F. Barré-Sinoussi,et al.  High Levels of Viral Replication during Primary Simian Immunodeficiency Virus SIVagm Infection Are Rapidly and Strongly Controlled in African Green Monkeys , 2000, Journal of Virology.

[179]  C. Rouzioux,et al.  Heterogeneity in HIV Suppression by CD8 T Cells from HIV Controllers: Association with Gag-Specific CD8 T Cell Responses1 , 2009, The Journal of Immunology.

[180]  C. Rouzioux,et al.  Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. , 2009, The Journal of clinical investigation.

[181]  M. Dierich,et al.  Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. , 2012, The Journal of allergy and clinical immunology.

[182]  Jerome H. Kim,et al.  Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family , 2012, Journal of Virology.

[183]  T. Elliott,et al.  Peptide antagonism as a mechanism for NK cell activation , 2010, Proceedings of the National Academy of Sciences.

[184]  R. Center,et al.  Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to ‘protective’ human leukocyte antigen-B alleles in HIV controllers , 2013, AIDS.

[185]  G. Silvestri,et al.  Nonhuman primate models in AIDS research , 2013, Current opinion in HIV and AIDS.

[186]  Jeffrey N. Martin,et al.  Phenotypic, Functional, and Kinetic Parameters Associated with Apparent T-Cell Control of Human Immunodeficiency Virus Replication in Individuals with and without Antiretroviral Treatment , 2005, Journal of Virology.

[187]  D. Watkins,et al.  Gag-Specific CD8+ T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression1 , 2007, The Journal of Immunology.

[188]  C. Rouzioux,et al.  Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial , 2012, AIDS.

[189]  E. Rosenberg,et al.  Transcriptional Profiling of Cd4 T Cells Identifies Distinct Subgroups of Hiv-1 Elite Controllers , 2022 .

[190]  G. Freeman,et al.  PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. , 2012, The Journal of clinical investigation.

[191]  Guido Ferrari,et al.  Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy , 2011, PloS one.

[192]  C. Chougnet,et al.  Increased IFN-gamma production by NK and CD3+/CD56+ cells in sexually HIV-1-exposed but uninfected individuals. , 2006, Clinical immunology.

[193]  T. Hirbod,et al.  Mucosal immune responses in the genital tract of HIV‐1‐exposed uninfected women , 2007, Journal of internal medicine.

[194]  J. Heeney,et al.  Prevention of SIV Rectal Transmission and Priming of T Cell Responses in Macaques after Local Pre-exposure Application of Tenofovir Gel , 2008, PLoS medicine.

[195]  D. Watkins,et al.  Gag-Specific CD 8 T Lymphocytes Recognize Infected Cells before AIDS-Virus Integration and Viral Protein Expression 1 , 2007 .

[196]  C. Hallahan,et al.  HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors , 2002, Nature Immunology.

[197]  M. Lederman,et al.  Response: Maraviroc intensification and microbial translocation. , 2013, Blood.

[198]  M. Carrington,et al.  Cutting Edge: Allele-Specific and Peptide-Dependent Interactions between KIR3DL1 and HLA-A and HLA-B12 , 2007, The Journal of Immunology.

[199]  E. Rosenberg,et al.  CD4+ T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. , 2011, The Journal of clinical investigation.

[200]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[201]  R. Desrosiers,et al.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. , 1992, Science.

[202]  Kristen K. Dang,et al.  Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals , 2010, PLoS pathogens.

[203]  J. Schmitz,et al.  Natural SIV Infection: Immunological Aspects , 2012 .

[204]  A. Ejaz,et al.  Complement as an Endogenous Adjuvant for Dendritic Cell-Mediated Induction of Retrovirus-Specific CTLs , 2010, PLoS pathogens.

[205]  C. Rouzioux,et al.  CD8 T-Cells from Most HIV-Infected Patients Lack Ex Vivo HIV-Suppressive Capacity during Acute and Early Infection , 2013, PloS one.

[206]  J Darbyshire,et al.  CD4+ count-guided interruption of antiretroviral treatment. , 2006, The New England journal of medicine.

[207]  K. Lichtenstein,et al.  Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study , 2015, Journal of acquired immune deficiency syndromes.

[208]  D. Scott‐Algara,et al.  Preserved Central Memory and Activated Effector Memory CD4+ T-Cell Subsets in Human Immunodeficiency Virus Controllers: an ANRS EP36 Study , 2007, Journal of Virology.

[209]  Z. Grossman,et al.  HIV preferentially infects HIV-specific CD4+ T cells , 2002, Nature.

[210]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[211]  O. Lambotte,et al.  Early and long-lasting alteration of effector CD45RA(-)Foxp3(high) regulatory T-cell homeostasis during HIV infection. , 2012, The Journal of infectious diseases.

[212]  S. Coppens,et al.  Immune and Viral Correlates of “Secondary Viral Control” after Treatment Interruption in Chronically HIV-1 Infected Patients , 2012, PloS one.

[213]  D. Scott‐Algara,et al.  Cutting Edge: Increased NK Cell Activity in HIV-1-Exposed but Uninfected Vietnamese Intravascular Drug Users 1 , 2003, The Journal of Immunology.

[214]  L. Weiss,et al.  The split personality of regulatory T cells in HIV infection. , 2013, Blood.

[215]  E. Thiel,et al.  Evidence for the cure of HIV infection by CCR5Δ32/Δ32 stem cell transplantation. , 2011, Blood.

[216]  M. Lederman,et al.  Effects of Recombinant Human Interleukin 7 on T-Cell Recovery and Thymic Output in HIV-Infected Patients Receiving Antiretroviral Therapy: Results of a Phase I/IIa Randomized, Placebo-Controlled, Multicenter Study , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[217]  K. Harada,et al.  Direct Observation of Vortex Dynamics in Superconducting Films with Regular Arrays of Defects , 1996, Science.

[218]  R. Schooley,et al.  Safety , Tolerability , and Mechanisms of Antiretroviral Activity of Pegylated Interferon Alfa-2 a in HIV-1 – Monoinfected Participants : A Phase II Clinical Trial , 2010 .

[219]  F. Barré-Sinoussi,et al.  African non human primates infected by SIV - why don't they get sick? Lessons from studies on the early phase of non-pathogenic SIV infection. , 2009, Current HIV research.

[220]  F. Barré-Sinoussi,et al.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. , 2009, The Journal of clinical investigation.

[221]  H. Schuitemaker,et al.  The Effect of Trim5 Polymorphisms on the Clinical Course of HIV-1 Infection , 2008, PLoS pathogens.

[222]  Y. Seo,et al.  Type I Interferon Modulates the Battle of Host Immune System Against Viruses , 2010, Advances in Applied Microbiology.

[223]  G. Freeman,et al.  Enhancing SIV-Specific Immunity In Vivo by PD-1 Blockade , 2008, Nature.

[224]  S. Lank,et al.  Major Histocompatibility Complex Class I Haplotype Diversity in Chinese Rhesus Macaques , 2013, G3: Genes, Genomes, Genetics.

[225]  Aarti Gautam,et al.  Cutting Edge: Experimentally Induced Immune Activation in Natural Hosts of Simian Immunodeficiency Virus Induces Significant Increases in Viral Replication and CD4+ T Cell Depletion1 , 2008, The Journal of Immunology.

[226]  S. Arya,et al.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. , 1995, Science.

[227]  A. Landay,et al.  Chloroquine Modulates HIV-1-Induced Plasmacytoid Dendritic Cell Alpha Interferon: Implication for T-Cell Activation , 2009, Antimicrobial Agents and Chemotherapy.

[228]  M. Malim,et al.  HIV Restriction Factors and Mechanisms of Evasion. , 2012, Cold Spring Harbor perspectives in medicine.

[229]  G. Boucher,et al.  Transcription factor FOXO3a controls the persistence of memory CD4+ T cells during HIV infection , 2008, Nature Medicine.

[230]  B. Walker,et al.  Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[231]  S. Rowland-Jones,et al.  Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.

[232]  T. Ndung’u,et al.  Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. , 2009, The Journal of infectious diseases.

[233]  J. van Lunzen,et al.  Expansion of HIV-specific T follicular helper cells in chronic HIV infection. , 2012, The Journal of clinical investigation.

[234]  B. Gazzard,et al.  Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. , 2012, JAMA.

[235]  L. Picker,et al.  Profound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis , 2009, The Journal of experimental medicine.

[236]  M. Proschan,et al.  B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. , 2010, Blood.

[237]  J. Mascola,et al.  Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. , 2012, Immunity.

[238]  M. Lederman,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Nature Medicine.

[239]  R. Chow,et al.  Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. , 1997, Clinical therapeutics.

[240]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[241]  J. Hiscott,et al.  Intact Type I Interferon Production and IRF7 Function in Sooty Mangabeys , 2013, PLoS pathogens.

[242]  Geneviève Boucher,et al.  HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation , 2009, Nature Medicine.

[243]  A. Lackner,et al.  HIV swiftly guts the immune system , 2005, Nature Medicine.

[244]  John W. Mellors,et al.  Prognosis in HIV-1 Infection Predicted by the Quantity of Virus in Plasma , 1996, Science.

[245]  P. Lebon,et al.  Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. , 2008, Blood.

[246]  R. Johnson,et al.  Simian Immunodeficiency Virus Infection Induces Expansion of α4β7+ and Cytotoxic CD56+ NK Cells , 2010, Journal of Virology.

[247]  Todd M. Allen,et al.  HIV-1 adaptation to NK cell mediated immune pressure , 2011, Nature.

[248]  R. Ribeiro,et al.  Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. , 2012, Blood.

[249]  E. Thiel,et al.  Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. , 2009, The New England journal of medicine.

[250]  C. Rouzioux,et al.  Elevated IP10 levels are associated with immune activation and low CD4+ T-cell counts in HIV controller patients , 2014, AIDS.

[251]  T. Beddoe,et al.  Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B , 2011, Nature.

[252]  A. Samri,et al.  Specific Phenotypic and Functional Features of Natural Killer Cells From HIV-Infected Long-Term Nonprogressors and HIV Controllers , 2010, Journal of acquired immune deficiency syndromes.

[253]  J. Hong,et al.  Potential Mechanism for Viral Escape Infection : T / B Cell Homeostasis , Activation , during Simian Immunodeficiency Virus T Cells + Follicular Helper , B , and CD 8 T + Spatial Alterations between CD 4 , 2012 .

[254]  J. Corbeil,et al.  Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques , 2013, Journal of Virology.

[255]  E. Rosenberg,et al.  Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction , 2007, Nature Immunology.

[256]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[257]  S. Elahi,et al.  Protective HIV-specific CD8+ T cells evade Treg cell suppression , 2011, Nature Medicine.

[258]  Michael D. George,et al.  Th17 cells, HIV and the gut mucosal barrier , 2010, Current opinion in HIV and AIDS.